Natera (NASDAQ:NTRA) Posts Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Natera (NASDAQ:NTRA) announced its quarterly earnings data on Tuesday. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31, Briefing.com reports. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the company earned ($0.95) EPS. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. Natera updated its FY 2024 guidance to EPS.

Natera Stock Performance

Shares of Natera stock opened at $135.12 on Wednesday. The firm has a market cap of $16.71 billion, a PE ratio of -55.15 and a beta of 1.53. The firm’s 50-day simple moving average is $125.09 and its 200-day simple moving average is $114.52. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera has a 1 year low of $46.96 and a 1 year high of $140.00.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. TD Cowen upped their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price target on shares of Natera in a research report on Friday, September 13th. Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group upped their price target on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $129.13.

Insider Activity

In other news, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the sale, the insider now owns 287,441 shares in the company, valued at approximately $34,783,235.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53. Following the sale, the chief executive officer now owns 200,710 shares in the company, valued at $23,866,426.10. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now owns 287,441 shares in the company, valued at approximately $34,783,235.41. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.